Large placebo-controlled clinical trials have shown that sodium-glucose cotransporter-2
inhibitors (SGLT2i) delay the deterioration of renal function and reduce cardiovascular …

Sodium-glucose co-transporter 2 inhibitors, also known as gliflozins, were developed as a
novel class of anti-diabetic agents that promote glycosuria through the prevention of glucose …

Background Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are antidiabetic oral drugs
that act on proximal renal tubules promoting renal glucose excretion. Although SGLT-2i …

Background C-reactive protein (CRP) levels are elevated in patients with abdominal aortic
aneurysms (AAA). However, it has not been investigated whether CRP contributes to AAA …

Introduction Diabetes mellitus (DM) has been proved to contribute to multiple comorbidities
that are risk factors for abdominal aortic aneurysm (AAA). Remarkably, evidences from …

Aortic aneurysms, including abdominal aortic aneurysms (AAAs), is the second most
prevalent aortic disease and represents an important cause of death worldwide. AAA is a …

Ventricular remodeling is a pathological process of ventricular response to continuous
stimuli such as pressure overload, ischemia or ischemia–reperfusion, which can lead to the …

Here we propose that SGLT2 inhibitors (SGLT2i), a class of drugs primarily used to treat type
2 diabetes could also be repositioned as anti-aging senomorphic drugs (agents that prevent …

Aim Signal transducer and activator of transcription (STAT) signaling is critical for the
pathogenesis of abdominal aortic aneurysms (AAAs). Though protein inhibitor of activated …

The incidence of abdominal aortic aneurysm (AAA) in the elderly is increasing year by year
with high mortality. Current treatment is mainly through surgery or endovascular intervention …